Author: healthprofessionalradio

Dr. Sammy Elmariah, Director, Interventional Cardiology Research at Massachusetts General Hospital discusses his recent research “Transfemoral Tricuspid Valve Replacement In Patients With Tricuspid Regurgitation: 30-day Results Of The Triscend Study” which was recently presented at the 2021 American College of Cardiology’s annual scientific meeting.  

Dr. Ellie Stang, a board-certified pediatrician and founder and CEO of ProgenyHealth, a healthcare company that applies evidence-based care management solutions to improve outcomes for premature and medically complex newborns, discusses how American women die in childbirth at a higher rate than in any other developed country, social determinants of health (SDOH), and how payers can effectively manage high-cost scenarios that require specialized expertise. 

Today, up to 60% of elderly persons develop delirium during hospitalization for an injury or unintentional fall. Dr. Franco Garcia, geriatric medicine specialist at Massachusetts General Hospital discusses data presented during the 2021 American Geriatrics Society’s Annual Meeting, that shows nutrition may be a modifiable risk factor for hospitalized, elderly orthopedic trauma patients. He shares key findings from his study, “Nutritional status is associated with new-onset delirium in elderly, acute care, orthopedic trauma patients: A single-center observational study”.  

Dr. Michael McCullar, CEO, and Dr. Hong Tang, Chief Medical Officer at OnQuality Pharmaceuticals, a clinical stage pharma company pioneering the discovery and development of targeted cancer supportive care therapies that address cancer treatment-related toxicities at the molecular level, discuss the company’s lead pipeline candidate, OQL011, the first targeted treatment for the severe cancer med side effect Hand Foot Skin Reaction (HFSR). OQL011 is currently in Phase 2 study at onco-dermatology clinics across the country. It is a topical ointment that can be applied to the hands and feet, acting locally to restore VEGFR signaling while avoiding any interference with the main cancer med mechanism of action.  

Newly appointed Chief Medical Officer of HD Medical, Inc., Shaun Setty, MD, discusses their flagship product, HD Steth, an FDA cleared Intelligent Stethoscope with ECG and PCG in a single device.  It allows providers to capture unsurpassed sound fidelity enhanced by visualization on the HD Steth Android or Apple iOS app. He also talks about HD Medical’s new HealthyU device, an all-in-one remote patient monitor, to be launched in the US in January 2022. 

Returning guest, Dr. Andrew Chan, MD, MPH, Gastroenterologist, Chief, Clinical and Translational Epidemiology Unit, Director of Cancer Epidemiology, Massachusetts General Cancer Center discusses his recent research “Associations Between Screening Lower Endoscopy and Colorectal Cancer Incidence in Younger Adults”, which was recently presented at the 2021 Digestive Disease Week annual scientific meeting.  

Rich Krueger, Co-founder and CEO of Hospital IQ, the leading provider of predictive hospital operations software, discusses how the company provides an operations management software platform that uses AI to anticipate and direct actions, enabling health systems to achieve and sustain peak operational performance.  He talks about the importance of streamlining provider operations post-pandemic and the value of building tech with scalability.  

Anne Quinn Young, MPH, Brand President of the MMRF discusses CureCloud, their latest platform designed to provide myeloma patents with their own genomic profile while building a database that combines genomic insights with clinical data to identify trends and support further developments. The CureCloud mission is to find and develop cures for all myeloma patients based on the fact that all patients can contribute to cures and each patient can benefit from the masses.  

John Whelan, President, CEO and Director of Inhalon Biopharma, a start-up immunotherapy company developing an inhaled “muco-trapping” antibody platform  for treating a variety of acute respiratory infections, discusses the award of a $7 million government contract from the U.S. Army Medical Research & Development Command (USAMRDC) to conduct a placebo-controlled Phase 1/2a study of the treatment in COVID-19 outpatients.  Inhalon’s treatment, IN-006, is a potent, neutralizing monoclonal antibody designed to trap pathogens like COVID-19 in airway mucus and clear them from the airways in minutes.  This technology offers a more immediate and scalable way of treating respiratory infections than current treatment options.  

Returning guest, Dr. Kathryn Lang, VP of Outcomes and Evidence at Guardant Health discusses the recent data shared at the 2021 American Society of Clinical Oncology (ASCO) on the investigational blood-based LUNAR-2 assay.  This data shows that it offers a high sensitivity in detecting colorectal cancer (CRC) in asymptomatic patients. This is particularly important now that the U.S. Preventive Services Task Force announced it has lowered the age for CRC screening from 50 to 45.